Intra-Cellular Therapies Investor Relations Material
Latest events
Study Result
Intra-Cellular Therapies
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Intra-Cellular Therapies Inc
Access all reports
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system. These diseases include schizophrenia and bipolar disorder, as well as other disorders such as depression and sleep disorders. The company's lead product candidate is latrepirdine, an orally available small molecule designed to be an efficacious anti-schizophrenia drug with a favorable safety profile and improved tolerability compared with existing antipsychotic treatments.
Key slides for Intra-Cellular Therapies Inc
Study Result
Intra-Cellular Therapies Inc
Corporate Presentation
Intra-Cellular Therapies Inc
Latest articles
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
3 May 2024
Microsoft's Journey to Becoming the World's Most Valuable Company
Explore Microsoft's rise from a garage startup to the world's most valuable company, highlighting Bill Gates' role in shaping the digital revolution.
3 May 2024
Bill Gates: The Man Who Put a Computer in Every Home
Explore the life of Bill Gates, from co-founding Microsoft to global philanthropy, and his lasting impact on the world.
2 May 2024
Ticker symbol
Country
🇺🇸 United States